PAVmed Inc. (PAVM) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay.
Analysis Summary
Trailing-twelve-month margins: gross margin -254.5%, operating margin -238.4%, net margin -107.9%.
At the current price of $3.92, PAVM has negative trailing earnings (P/E not meaningful) and an ROE of -33.51%. Market capitalisation stands at $25M.
Balance sheet quality for PAVM: current ratio of 0.2, net debt of $11.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of -$5.21B represents -1298254% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $3.92 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.70 |
| EV / EBITDA | -2.65 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -33.51% |
| Return on Invested Capital | -72.77% |
| Return on Assets | -30.06% |
| Gross Margin | -254.46% |
| Operating Margin | -23842.86% |
| Net Margin | -10794.64% |
Financial Health
| Debt / Equity | 0.49 |
| Current Ratio | 1.19 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PAVM | PAVmed Inc. | $25M | 0.70 | -33.5% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -22.53% |
| 3 months | -24.03% |
| Year-to-date | -40.79% |
| 1 year | -67.68% |
| 3 years | -97.03% |
| 5 years | -99.89% |
52-Week Range
| 52-week High | $28.44 |
| 52-week Low | $3.70 |
| Avg Volume (90d) | 26K |
Related companies: ADVB · APVO · BMRA · BNR · DHAI · HSCS · IINN
Explore sector: Healthcare · Medical - Devices
More sections of PAVM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks